Trials / Completed
CompletedNCT02458638
A Study of Atezolizumab in Advanced Solid Tumors
An Open-Label, Multicohort, Phase II Study of Atezolizumab in Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 474 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary efficacy objective for this study is to evaluate non-progression rate (NPR) at 18 weeks in participants with advanced solid tumors treated with atezolizumab, defined as the percentage of participants with complete response (CR), partial response (PR), or stable disease (SD) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1, or according to disease-specific criteria for prostate cancer and malignant pleural mesothelioma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody | Atezolizumab will be given as IV infusion over 60 minutes on Day 1 of Cycle 1, then over 30 minutes (as tolerated) on Day 1 of each subsequent 3-week cycle. |
Timeline
- Start date
- 2015-07-16
- Primary completion
- 2018-04-04
- Completion
- 2020-07-28
- First posted
- 2015-06-01
- Last updated
- 2021-06-04
- Results posted
- 2021-06-04
Locations
48 sites across 18 countries: United States, Austria, Brazil, Canada, Denmark, Finland, France, Germany, Ireland, Italy, Netherlands, Norway, Poland, Russia, Spain, Switzerland, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT02458638. Inclusion in this directory is not an endorsement.